EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges

Judit Moldvay, József Tímár

Pathology and Oncology Research · 04.01.2024 · 29

DOI: 10.3389/pore.2023.1611580 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathology and Oncology Research, online erschienen am 04.01.2024. Verfasst von Judit Moldvay und 1 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Pulmonology, Budapest, Hungary. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Acetonitriles, Piperazines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS mutant lung cancer is the most prevalent molecular subclass of adenocarcinoma (LUAD), which is a heterogenous group depending on the mutation-type which affects not only the function of the oncogene but affects the biological behavior of the cancer as well. Furthermore, KRAS mutation affects radiation sensitivity but leads also to bevacizumab and bisphosphonate resistance as well. It was highly significant that allele specific irreversible inhibitors have been developed for the smoking associated G12C mutant KRAS (sotorasib and adagrasib). Based on trial data both sotorasib and adagrasib obtained conditional approval by FDA for the treatment of previously treated advanced LUAD. Similar to other target therapies, clinical administration of KRASG12C inhibitors (sotorasib and adagrasib) resulted in acquired resistance due to various genetic changes not only in KRAS but in other oncogenes as well. Recent clinical studies are aiming to increase the efficacy of G12C inhibitors by novel combination strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsAcetonitrilesPiperazinesPyrimidinesHumansProto-Oncogene Proteins p21(ras)MutationBiology

Stichwörter der Autor:innen

G12C mutationKRASadagrasiblung adenocarcinomasotorasib

Substanzen

adagrasibProto-Oncogene Proteins p21(ras)AcetonitrilesPiperazinesPyrimidines

Autor:innen und Institutionen

  • National Institute of Pulmonology, Budapest, Hungary.
  • Pulmonology Clinic, Szentgyörgyi A. University, Szeged, Hungary.
  • Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary.

Zitieren

APA

Moldvay, J., & Tímár, J. (2024). KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges. Pathology and Oncology Research, 29. https://doi.org/10.3389/pore.2023.1611580

Vancouver

Moldvay J, Tímár J. KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges. Pathology and Oncology Research. 2024;29. doi:10.3389/pore.2023.1611580

BibTeX
@article{Moldvay2024,
  author = {Moldvay, Judit and Tímár, József},
  title = {KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges},
  journal = {Pathology and Oncology Research},
  year = {2024},
  volume = {29},
  doi = {10.3389/pore.2023.1611580}
}
Kostenlos starten →